CPI-169

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

CPI-169 is a potent, and selective EZH2 inhibitor with IC50 of 0.24 nM, 0.51 nM, and 6.1 nM for EZH2 WT, EZH2 Y641N, and EZH1, respectively.

CPI-169 is a potent inhibitor of enhancer of zeste homolog 2 (EZH2) with an IC50 value of <1nM for polycomb repressive complex 2 (PRC2). CPI-169 was shown to inhibit tumor growth in a NHL xenograft model, reducing global H3K27me3.1 It has also been shown to synergize with the B-cell lymphoma inhibitor, ABT-199, to suppress the growth of NHL cell lines.

CPI-169; CPI 169; CPI169

Angiogenesis

ALK

EZH1; EZH2 WT; EZH2 Y641N

Cancer

——

1450655-76-1

528.66

C27H36N4O5S

98%

DMSO : ≥ 59 mg/mL. 111.60 mM

CCS(=O)(=O)N1CCC(CC1)C(C)n1c2ccccc2c(C(=O)NCc2c(OC)cc(C)[nH]c2=O)c1C

(R,Z)-1-(1-(1-(ethylsulfonyl)piperidin-4-yl)ethyl)-N-((2-hydroxy-4-methoxy-6-methylpyridin-3-yl)methyl)-2-methyl-1H-indole-3-carbimidic acid

(-20℃)

With Ice Pack

≥ 2 years